| Location: | Pennsylvania |
|---|---|
| Posted: | Feb 1, 2026 |
| Due: | Feb 14, 2026 |
| Agency: | HEALTH AND HUMAN SERVICES, DEPARTMENT OF |
| Type of Government: | Federal |
| Category: |
|
| Solicitation No: | NIH-26-006363-IntentNotice |
| Publication URL: | To access bid details, please log in. |
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
This notice is not a request for competitivequotations or capability statements. The intent of this notice is for informational purposes only.
Please do not call or submit questions/inquiries via email, concerning this presolicitation notice update.
------------------------------------------------------------------------------------------------------------------------
The intent is to award a contract on a solesource basis for Nucleic acid–based reagents for in vivo transient protein expression for the National Cancer Institute and Center for Cancer Research to:
Trustees of The University of Pennsilvania - Penn Medicine
3451 Walnut Street
Philadelphia, PA
19104, USA
The supplies required are nucleic acid-based reagents.
The proposed work focuses on the use of nucleic acid-based reagents to investigate preventive strategies against viral infection of HIV/Simian Immunodeficiency virus (SIV) and HTLV in preclinical models. The proposed studies will utilize nucleic-acid based reagents that express viral antigens as a preventive treatment to be tested in appropriate models.
Nucleic acid-based reagents have been used in prior preclinical studies, conducted by the AMRVS, as preventive countermeasures against viral infections, demonstrating the ability to induce protective immune responses in relevant experimental models. Previous work has shown that such reagents can be designed to express viral antigens that are safe and confer protection against the target pathogen. Collectively, these findings support further preclinical studies as preventive strategies. The requested reagents will provide broader activity against related viral subtypes and other cancer-inducing viruses. It is important to use the same supplier for these reagents in order to ensure consistency with materials used in previous preclinical studies. These reagents can vary in formulation, synthesis methods and purity, and such differences may introduce variability that complicates interpretation of experimental results. Using reagents from the same suppliers enables direct comparison with previously generated data, support reproducibility and ensure continuity in experimental design and data analysis.

With GovernmentContracts, you can:
...Interpretation, Document Translation and Transcriptions and services for the Visually and Hearing-Impaired... Project: ...
Montgomery County
Bid Due: 6/05/2026
...Food Service Freezer/Cooler Equipment, and Walk-In Cooler Hempfield Area School District invites... Approved ...
Hempfield AreaSchool District
Bid Due: 6/23/2026
...: ITQ Advertisement Type: Service Materials Service & Materials PW Construction Agency Construction... ...
State Government of Pennsylvania
Bid Due: 2/28/2031
...Contractors to perform interpretation and translation services/materials to Commonwealth of Pennsylvania's...: ITQ Advertisement ...
State Government of Pennsylvania
Bid Due: 12/31/2031